Copyright
©The Author(s) 2023.
World J Gastroenterol. May 14, 2023; 29(18): 2850-2863
Published online May 14, 2023. doi: 10.3748/wjg.v29.i18.2850
Published online May 14, 2023. doi: 10.3748/wjg.v29.i18.2850
Figure 3 Differences in disease-specific survival between patients with gastric cancer who underwent cytoreductive surgery and 60 min or 90 min hyperthermic intraperitoneal chemotherapy.
The dotted line represents median survival. CRS: Cytoreductive surgery; HIPEC: Hyperthermic intraperitoneal chemotherapy.
- Citation: Steinhoff H, Acs M, Blaj S, Dank M, Herold M, Herold Z, Herzberg J, Sanchez-Velazquez P, Strate T, Szasz AM, Piso P. Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases. World J Gastroenterol 2023; 29(18): 2850-2863
- URL: https://www.wjgnet.com/1007-9327/full/v29/i18/2850.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i18.2850